article

Expert view: Mitigating risk with modern microbial identifications

2
SHARES

Posted: 28 October 2020 | | No comments yet

Species-level microbial identification (ID) is a growing requirement under good manufacturing practice (GMP) to ensure patient safety.

Join our free webinar: The Future of Sterility Testing: One-Day Results with Advanced RT-rt PCR Technology

Join this webinar to find out how RT-rt PCR is revolutionising sterility testing and discover a unique approach that provides reliable one-day results and enhanced sensitivity and detection capabilities.

Date: 5 Nov | Time: 15:00 BST

REGISTER NOW TO SECURE YOUR SPOT <<<

Can’t attend live? No worries – register to receive the recording post-event.

 

 

Reserve your FREE place

 


Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.

20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion

This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.

Key learning points:

  • Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
  • Learn about ITM’s implementation journey and considerations when evaluating the technology
  • Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).

Don’t miss your chance to learn from experts in the industry – Register for FREE

 

Over the last few years, there have been many product recalls associated with fungal contamination. Of these, few had associated species-level IDs, compared with bacterial contamination recalls of which most had a species ID.

In the past, microbiologists may have been limited in their ability to provide an accurate species-level ID. Even now, many quality control (QC) labs still use macroscopy and microscopy to identify any fungal isolates from their facilities. With the complexity of their microscopic structures, it is no wonder that fungal ID using this technique requires training and years of experience and remains unreliable.

There are commercial systems available to aid in fungal ID but often these are limited by the technology itself
(eg, phenotypic systems have long been recognised as less accurate and precise than genotypic systems by the US Food and Drug Administration [FDA]). In recent years, MALDI-TOF has become increasingly commonplace as it provides a reliable method for identifying microorganisms. However, all ID systems rely on a library that is used to compare the result and generate the ID. If something is not in that library, there may be no ID or, perhaps even worse, an incorrect ID and subsequent incorrect assessment of risk. This seems to be an area often overlooked; yet it should be evaluated per USP (1113) and EP (5.1.6) guidance.

While some microbiologists might see newer technologies as a loss of skills, but the real skill does not come from generating the ID; it comes from understanding the impact that the species will have on their production process or product. This knowledge adds real impact and allows for proactive decision making. This not only ensures patient safety but also adds financial benefits to the manufacturer through prevention of interventions or batch scrappage.

Share via
Share via